Logo

Genome Medical

Genome Medical, Hereditary Neuropathy Foundation Partner for Charcot-Marie-Tooth Disease Testing

The CMT Genie Project aims to provide faster and more equitable access to genetic testing for the CMT community via virtual services.

Seven Bridges Genomics to Foster Partnerships Between Health Systems, Pharmas With New Subsidiary
Premium

The Unified Patient Network expects pharmaceutical companies to sponsor whole-genome sequencing for patients from health systems for research and clinical purposes.

Genome Medical Raises $60M in Series C Round, to Acquire Telehealth Firm GeneMatters

GeneMatters provides genetic counseling, care delivery software, and patient engagement tools and will become a subsidiary of Genome Medical.

Invitae, PCT Therapeutics, Genome Medical Partner to Offer Genetic Testing for Cerebral Palsy

The testing program will be available for patients in the US who have symptoms or a diagnosis of cerebral palsy but no evidence of brain injury.

Genome Medical Raises $14M in Extended Series B Financing

The company plans to use the funds to improve patient engagement and navigation within its Genome Care Delivery technology platform.

Breaking News
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.